Preparation of 10-shogaol nano-liposome and application of 10-shogaol nano-liposome in treatment of sepsis lung injury
By preparing 10-gingerenol nanoliposomes, using liposomes composed of DPPC, cholesterol and DSPE-mPEG2000, the problem of low solubility and bioavailability of 10-gingerenol in the human body was solved, and ALI was achieved Effective targeted therapy reduces inflammatory factor expression and oxidative stress, and improves lung damage.
Patent Information
- Application Number
- CN202411396183.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-08
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-10-08
AI Technical Summary
10-Gingerenol, as a hydrophobic substance, has low solubility and bioavailability in the human body, resulting in the inadequacy of its efficacy in the treatment of acute lung injury (ALI).
Prepare 10-gingerenol nanoliposomes, and adjust the drug-lipid ratio and liposome component ratio, and use DPPC, cholesterol and DSPE-mPEG2000 as the main components to form nanolipids with excellent encapsulation rate and drug loading amount. , used to target the treatment of septic lung injury caused by LPS.
Improve the biocompatibility and stability of 10-gingerenol, significantly reduce the expression levels of lung inflammatory factors IL-6, iNOS and TNF-α, relieve H2O2-induced oxidative stress, and reduce lung edema , significantly improved the therapeutic effect of ALI.
Smart Images

Figure BDA0005073816380000051 
Figure HDA0005073816390000011 
Figure HDA0005073816390000012
Abstract
Description
Technical Field
[0001] The invention relates to the field of medical technology, and in particular to the preparation of 10-shogaol nanoliposomes and the application thereof in treating septic lung injury. Background Art
[0002] Acute lung injury (ALI) is a common clinical syndrome of diffuse pulmonary inflammation. The disease is characterized by reduced lung volume, decreased lung compliance, and severe ventilation / perfusion imbalance. Clinically, it manifests as progressive hypoxemia and respiratory distress, and lung imaging shows non-uniform exudative lesions. When ALI patients have lung damage to a certain extent, they are prone to acute respiratory distress syndrome (ARDS). The pathogenesis of ALI is complex, and the mortality rate of patients is as high as 30% to 50%. Therefore, it is urgent to develop drugs with good efficacy against ALI.
[0003] At present, studies have shown that gingerol has certain anti-inflammatory activity in in vitro cell experiments, and 6-gingerol has shown a therapeutic effect on ALI. However, the efficacy of 10-gingerol in the treatment of ALI remains to be explored, and this compound is a hydrophobic substance. How to improve its solubility and bioavailability in the human body so that it can better play a role in treating ALI is a major problem that needs to be solved urgently. Summary of the invention
[0004] To solve the above problems, the present invention provides the preparation of 10-shogaol nanoliposomes and the application of the septic lung injury treatment.
[0005] According to one aspect of the present invention, a 10-shogaol nanoliposome is provided, comprising original drug 10-shogaol and liposome encapsulating the original drug 10-shogaol, wherein the mass ratio of the original drug 10-shogaol to the liposome is 1:(3-10); the liposome is prepared from DPPC, cholesterol and DSPE-mPEG2000, and the molar ratio of DPPC, cholesterol and DSPE-mPEG2000 is (75-80):(18-22):3.
[0006] The 10-shogaol nanoliposomes provided by the present invention obtain liposomes with excellent encapsulation rate and drug loading by adjusting the drug-lipid ratio (the mass ratio of the original drug 10-shogaol to the liposome) and the ratio of each component in the liposome. The obtained 10-shogaol nanoliposomes have good biocompatibility, safety, stability and therapeutic effectiveness, and can be used for targeted treatment of septic lung injury caused by LPS, reducing pulmonary edema, alleviating oxidative stress induced by H2O2, and reducing the expression levels of proinflammatory factors IL-6, iNOS and TNF-α.
[0007] In some embodiments, the mass ratio of the original drug 10-shogaol to the liposome is 1:(4-6).
[0008] In some embodiments, the drug loading of 10-shogaol nanoliposomes is 7-16%.
[0009] In some embodiments, the encapsulation efficiency of 10-shogaol in 10-shogaol nanoliposomes is 60-80%.
[0010] In some embodiments, the 10-shogaol nanoliposomes are spherical with an average diameter of 126±5 nm.
[0011] In some embodiments, the zeta potential of 10-shogaol nanoliposomes is -22±3 mV.
[0012] According to another aspect of the present invention, a method for preparing 10-shogaol nanoliposomes is provided, comprising the following steps:
[0013] S1. DPPC, cholesterol, DSPE-mPEG2000 and 10-shogaol were dissolved in a solvent, and the solvent was removed by rotary evaporation to obtain a film;
[0014] S2. Add an aqueous medium to the film obtained in step S1 to hydrate it to obtain a suspension, and then place it on ice for ultrasonication. After the ultrasonication, 10-shogaol nanoliposomes can be obtained.
[0015] In some embodiments, the solvent used in step S1 is chloroform.
[0016] In some embodiments, the amounts of DPPC, cholesterol, DSPE-mPEG2000 and 10-shogaol added in step S1 are 44 mg, 6 mg, 2 mg and 10 mg, respectively.
[0017] In some embodiments, the amount of solvent used in step S1 is 5 mL.
[0018] In some embodiments, the rotary evaporation in step S1 is performed at a pressure of 230 mbar.
[0019] In some embodiments, the rotary evaporation in step S1 is performed at a temperature of 40°C.
[0020] In some embodiments, the aqueous medium used in step S2 is PBS buffer.
[0021] In some embodiments, the amount of aqueous medium added in step S2 is 5 mL.
[0022] In some embodiments, the hydration in step S2 is performed at a temperature of 60°C.
[0023] In some embodiments, the hydration in step S2 is performed under stirring conditions, and the stirring speed is 300 rpm.
[0024] In some embodiments, the hydration time in step S2 is 30 min.
[0025] In some embodiments, the power of ultrasound in step S2 is 15-25%.
[0026] It should be noted that the above-mentioned ultrasonic power of 15-25% means that the ultrasonic power is 15-25% of the maximum power of the instrument.
[0027] In some embodiments, the ultrasound mode in step S2 is 15 seconds per ultrasound and 15 seconds of pause.
[0028] In some embodiments, the ultrasonication time in step S2 is 15 to 45 minutes.
[0029] In some embodiments, step S2 further includes the steps of filtration, ultrafiltration and volume fixing after the ultrasound is completed.
[0030] In some embodiments, the filtration is as follows: collecting the suspension after ultrasonic dispersion, filtering and collecting it with a 0.22 μm filter, and taking the filtrate. The purpose of this filtration step is to filter out the large-diameter agglomerates that have not been dispersed.
[0031] In some embodiments, the ultrafiltration is as follows: the filtrate is transferred to an ultrafiltration tube with a MWCO of 100,000 and centrifuged at 3,000 rpm for 1 hour. The purpose of this ultrafiltration step is to remove the remaining solvent and free 10-gingerol monomers.
[0032] In some embodiments, the above-mentioned volume adjustment is: using PBS buffer to adjust the volume of 10-shogaol nanoliposomes in the ultrafiltration tube to 3 mL for later use.
[0033] According to another aspect of the present invention, provided is the use of 10-shogaol nanoliposomes in preparing a drug for treating septic lung injury.
[0034] According to another aspect of the present invention, there is provided a use of 10-shogaol nanoliposomes in preparing a drug for treating H2O2-induced oxidative stress.
[0035] The 10-shogaol nanoliposome provided by the present invention can reduce the level of reactive oxygen species, superoxide dismutase activity and malondialdehyde level in cells, and thus can be used to alleviate oxidative stress induced by H2O2.
[0036] According to another aspect of the present invention, provided is the use of 10-shogaol nanoliposomes in the preparation of anti-inflammatory drugs.
[0037] The 10-shogaol nanoliposome provided by the present invention can reduce the expression levels of pro-inflammatory factors IL-6, iNOS and TNF-α, and thus can also be used to prepare anti-inflammatory drugs.
[0038] Compared with the prior art, the present invention has the following beneficial effects:
[0039] The present invention obtains 10-shogaol nanoliposomes with excellent drug loading and encapsulation rate by adjusting the drug-lipid ratio and the ratio of each component in the liposome. The liposome can target the lungs, reduce the expression levels of inflammatory factors such as IL-6, iNOS and TNF-α, relieve oxidative stress induced by H2O2, and treat septic lung injury caused by LPS. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] Figure 1 Schematic diagram of transmission electron microscopy and particle size comparison of different groups of liposomes of the present invention;
[0041] Figure 2 This is a schematic diagram comparing the ZETA potentials of different groups of liposomes of the present invention;
[0042] Figure 3 Schematic diagram showing the comparison of particle size distribution and PDI of different groups of liposomes in the present invention at 7 days;
[0043] Figure 4 The effects of different concentrations of different groups of the present invention on HUVEC cell viability;
[0044] Figure 5 The effects of different concentrations of different groups of the present invention on the viability of RAW 264.7 cells;
[0045] Figure 6 The effects of different concentrations of different groups of the present invention on the viability of A549 cells;
[0046] Figure 7 This is a schematic diagram showing the effect of working concentrations of different groups of the present invention on the activity / toxicity of HUVEC;
[0047] Figure 8 Schematic diagram showing the effects of working concentrations of different groups of the present invention on the activity / toxicity of A549 cells;
[0048] Fig. 9 A schematic diagram of the compatibility of different concentrations of different groups of the present invention with blood;
[0049] Fig.10 The effects of different groups of the present invention on the mRNA expression levels of pro-inflammatory factors IL-6, IL-1β and TNF-α in RAW264.7 cells intervened by LPS;
[0050] Fig.11 The effects of different groups of the present invention on the level of reactive oxygen species in H2O2-induced oxidative stress;
[0051] Fig.12 The effects of different groups of the present invention on superoxide dismutase activity in H2O2-induced oxidative stress;
[0052] Fig.13 The effects of different groups of the present invention on the level of malondialdehyde in H2O2-induced oxidative stress;
[0053] Fig.14 The effects of different groups of the present invention on pathological damage of lung and other tissues in mice with septic lung injury induced by LPS;
[0054] Fig.15 The effects of different groups of the present invention on the lung index of mice with septic lung injury induced by LPS;
[0055] Fig.16 The present invention shows the effects of different groups on the mRNA expression levels of pro-inflammatory factors IL-6, IL-1β and TNF-α in the lung tissues of mice with septic lung injury induced by LPS. DETAILED DESCRIPTION
[0056] The present invention is further described in detail below in conjunction with the examples and drawings, but the implementation of the present invention is not limited thereto. The experimental methods in the following examples are conventional methods unless otherwise specified. The experimental materials used in the following examples are purchased from the market unless otherwise specified.
[0057] Example 1
[0058] A method for preparing 10-shogaol nanoliposomes comprises the following steps:
[0059] S1. Weigh 44 mg, 6 mg and 2 mg of DPPC, cholesterol and DSPE-mPEG2000 in a molar ratio of 77:20:3, respectively, and add them into a 500 mL round-bottom flask; dissolve 10 mg of 10-shogaol in chloroform and add it into the round-bottom flask, mix well until the total volume of chloroform in the round-bottom flask is 5 mL; perform rotary evaporation in a 40°C water bath and 230 mbar until the chloroform is completely evaporated and a thin film is formed on the wall of the round-bottom flask; wherein the mass ratio of 10-shogaol to liposomes is 1:5.2;
[0060] S2. Add 5 mL of PBS buffer to the round-bottom flask of step S1, stir at 300 rpm on a magnetic stirrer at 60° C. for 30 min until the film is completely hydrated to obtain a liposome suspension, transfer the liposome suspension to a 20 ml sample bottle, place it on ice for ultrasonication, the ultrasonic power is 20%, the ultrasonic mode is 15 s per ultrasonication, pause for 15 s, and end the ultrasonication after a cycle of 30 min; collect the suspension after ultrasonic dispersion, filter and collect it using a 0.22 μm filter, and take the filtrate; transfer the filtrate to a 100000 MWCO ultrafiltration tube and centrifuge it at 3000 rpm for 1 h, use PBS buffer to make the 10-gingerol nanoliposomes in the ultrafiltration tube fixed to 3 mL, and set aside.
[0061] The 10-shogaol nanoliposomes obtained in this example are denoted as SA-Lipo. The 10-shogaol nanoliposomes obtained in this example are characterized, and it can be measured that the drug loading of the 10-shogaol nanoliposomes is 13.5%, and the encapsulation efficiency of 10-shogaol is 78.4%; the 10-shogaol nanoliposomes are spherical, with an average diameter of 126.03 nm, as shown in FIG. Figure 1 As shown; the Zeta potential of 10-shogaol nanoliposomes is -22.14mV. Figure 2 shown.
[0062] The method for determining the drug loading of 10-shogaol nanoliposomes in this embodiment comprises the following steps:
[0063] The 10-shogaol nanoliposome solution obtained by constant volume in step S2 was diluted in acetonitrile at a ratio of 1:10, and ultrasonically disrupted for 1 hour to release the liposome-encapsulated 10-shogaol, collected and centrifuged at 12000 rpm for 10 minutes, and the supernatant was taken to detect the highest absorption peak of the drug with an ultraviolet spectrophotometer to determine the optimal absorption wavelength (281.5 nm) and the OD value of the drug, and the drug concentration of SA-Lipo was calculated based on the standard curve.
[0064] Example 2
[0065] A method for preparing 10-shogaol nanoliposomes, which is different from Example 1 only in that:
[0066] The mass ratio of 10-shogaol to liposome used in step S1 is 1:7.8, wherein the mass of 10-shogaol is 10 mg, and the mass of DPPC, cholesterol, and DSPE-mPEG are 66 mg, 9 mg, and 3 mg, respectively.
[0067] Example 3
[0068] A method for preparing 10-shogaol nanoliposomes, which is different from Example 1 only in that:
[0069] The mass ratio of 10-shogaol to liposome used in step S1 is 1:4.2, wherein the mass of 10-shogaol is 10 mg, and the mass of DPPC, cholesterol, and DSPE-mPEG are 35.2 mg, 4.8 mg, and 1.6 mg, respectively.
[0070] The 10-shogaol nanoliposomes obtained in Examples 1 to 3 were characterized to show that when the dosage of 10-shogaol was kept at 10 mg but the drug-lipid ratio was different, the encapsulation efficiency and drug loading of the obtained liposomes were different, as shown in Table 1. When the drug-lipid ratio was 1:5.2, the encapsulation efficiency of the obtained liposomes (Example 1) was the highest.
[0071] Table 1. Data on drug loading, drug loading rate and encapsulation rate of liposomes obtained in Examples 1 to 3
[0072]
[0073] Comparative Example 1
[0074] A method for preparing nanoliposomes, which differs from Example 1 only in that:
[0075] In step S1, 10-shogaol is not added.
[0076] The nanoliposomes obtained in this comparative example are denoted as Lipo.
[0077] The liposomes obtained in Example 1 and Comparative Example 1 were characterized, and the experimental results are as follows: Figures 1-2 As shown: the size of Lipo is 126-158nm, the size of SA-Lipo is 109-158nm, and the average sizes of Lipo and SA-Lipo are about 127.87nm and 126.03nm, respectively. Zeta potential shows that Lipo and SA-Lipo are both negatively charged, with average potentials of -12.43mV and -22.14mV, respectively. Transmission electron microscopy observations show that Lipo and SA-Lipo have a relatively uniform spherical morphology, and the diameter size is within the range of the results measured by DLS.
[0078] Take 1 mL of Lipo and SA-Lipo suspension respectively, add 9 ml of ultrapure water to dilute the suspension 10 times, and use the DLS method of the particle size analyzer to detect the size distribution and dispersion index (PDI) of Lipo and SA-Lipo for 7 consecutive days.
[0079] Figure 3 The results showed that the size and PDI of Lipo and SA-Lipo were stable at about 120 nm and 0.2, respectively, indicating that the SA-Lipo provided by the present invention has good stability for at least one week.
[0080] Next, cell and animal experiments were conducted using the 10-shogaol nanoliposomes SA-Lipo prepared in Example 1, the nanoliposomes Lipo in Comparative Example 1, and free 10-shogaol monomer 10-Shogaol (denoted as SA) to explore their pharmacological effects.
[0081] 1. Cell experiments and related index determination
[0082] 1. Biosafety Assessment
[0083] 1) Effects of different concentrations of SA-Lipo on HUVEC cell viability
[0084] The cytotoxicity of the drug was determined using the Cell Counting Kit-8 (CCK-8) kit (Jinxin Biotechnology, #GxCK08). HUVEC cells were cultured at 4×10 3 The cells / well were inoculated in a 96-well culture plate at a density of 1.50 μg / well and cultured for 24 hours. The cells were treated with DMEM medium (containing 10% FBS, i.e., 10% fetal bovine serum) containing different concentration gradients of Lipo, SA, and SA-Lipo. After 24 hours, the supernatant was discarded, 10 μL of CCK8 solution and 100 μL of DMEM medium were added to each well, and the plates were placed in an incubator and incubated in the dark for 1-2 hours. Finally, the absorbance was measured at a wavelength of 450 nm.
[0085] Figure 4 The results showed that within the concentration range of 0.5-8 μM, the SA-Lipo of the present invention had almost no effect on cell viability, and at 8 μM, the cell viability was better than that of the free monomer group.
[0086] 2) Effects of different concentrations of SA-Lipo on RAW264.7 cell viability
[0087] The cytotoxicity of the drug was determined using the CCK-8 kit. RAW 264.7 cells were cultured at 1×10 4 The cells were inoculated at a density of 100 μg / well in a 96-well culture plate and cultured for 24 hours. The cells were treated with DMEM medium containing different concentration gradients of Lipo, SA and SA-Lipo. After 24 hours, the supernatant was discarded, 10 μl of CCK8 solution and 100 μl of DMEM medium were added to each well, and the cells were placed in an incubator in the dark for 1-2 hours. Finally, the absorbance was measured at a wavelength of 450 nm.
[0088] Figure 5 The results showed that within the concentration range of 0.5-8 μM, the SA-Lipo of the present invention had almost no effect on the viability of RAW264.7 cells.
[0089] 3) Effects of different concentrations of SA-Lipo on A549 cell viability
[0090] CCK-8 was used to determine the cytotoxicity of the drug. 3 The cells / well were inoculated in a 96-well culture plate at a density of 1.50 μg / well and cultured for 24 hours. The cells were treated with DMEM medium (containing 10% FBS) containing different concentration gradients of Lipo, SA and SA-Lipo. After 24 hours, the supernatant was discarded, 10 μl of CCK8 solution and 100 μl of DMEM medium were added to each well, and the plates were placed in an incubator in the dark for 1-2 hours. Finally, the absorbance was measured at a wavelength of 450 nm.
[0091] Figure 6 The results showed that within the concentration range of 0.5-8 μM, the SA-Lipo of the present invention had almost no effect on the viability of A549 cells.
[0092] 4) Activity and toxicity detection of SA-Lipo on HUVEC and A549 cells
[0093] Calcein / PI cell activity and cytotoxicity detection kit (Biyuntian, #C2015M) was used to detect the activity and toxicity of drugs on cells. A549 or HUVEC were cultured in a 12-well culture plate for 24 hours, and the cells were treated with DMEM medium (containing 10% FBS) containing Lipo, SA and SA-Lipo, respectively. The control group was added with DMEM medium (containing 10% FBS). After 24 hours, the supernatant was discarded, and the prepared Calcein AM / PI detection working solution was added to each well, and incubated at 37°C in the dark for 30 minutes. After the incubation, the staining effect was observed under a fluorescence microscope.
[0094] Figure 7 , 8 The results showed that the SA-Lipo of the present invention had no effect on the activity of HUVEC and A549 cells. Based on the above CCK8 experimental results, 2 μM was finally selected as the working concentration of SA and SA-Lipo.
[0095] 5) Schematic diagram of the compatibility of SA-Lipo with blood at different concentrations
[0096] Take 2mL of normal rat whole blood, add an appropriate volume of sodium heparin solution and centrifuge (5000rpm, 5min, room temperature), discard the upper plasma, dilute and resuspend the precipitate with an appropriate amount of physiological saline, and wash 3 times until the supernatant is blood-free. Take an appropriate amount of red blood cells from the lower layer in a centrifuge tube, add physiological saline to prepare a 2% red blood cell solution, and then add different concentration gradients of Lipo, SA and SA-Lipo, pure water and PBS as positive and negative controls respectively. After standing at room temperature for 3h, centrifuge at 1000rpm for 5min and take photos and record them, then aspirate the supernatant and detect it on an enzyme reader at 540nm to calculate the hemolysis rate. Hemolysis rate = (Aa-A0) / (Ab-A0)×100%. (Aa, A0 and Ab are the absorbance of the experimental group, negative control group, and positive control group, respectively)
[0097] Fig. 9 The results show that the SA-Lipo of the present invention is incompatible with blood and has good biocompatibility.
[0098] 2. Anti-inflammatory effect study: Effect of SA-Lipo on the mRNA expression of pro-inflammatory factors IL-6, IL-1β and TNF-α in RAW264.7 cells treated with LPS
[0099] RAW264.7 was cultured in a 12-well culture plate for 24 hours, and the cells were treated with DMEM medium (containing 10% FBS) containing Lipo, SA and SA-Lipo, respectively. The control group and model group were added with DMEM medium containing 10% FBS). The supernatant was discarded after 12 hours, and the cells were treated with DMEM medium (containing 10% FBS) containing 100ng / ml LPS (Sigma, L2880#) in other groups except the control group. The supernatant was discarded after 4 hours, and the cells were treated with DMEM medium (containing 10% FBS) containing Lipo, SA and SA-Lipo, respectively. The supernatant was discarded after 6 hours and the cells were collected.
[0100] According to the instructions of the RNA extraction kit (Tiangen Biotech, China), RAW264.7 cells were used to extract total RNA using RZ reagent, the extracted RNA content was determined by Nanodrop, and the mRNA was reverse transcribed into cDNA using the PrimeScript RT kit and gDNA EraserPerfect Real Time (Takara Bio, China). The cDNA of each sample was used as a template to perform qRT-PCR amplification and detection of the target genes (IL-6, IL-1β, TNF-α and α-Tubulin) to analyze the mRNA expression of each target gene. After the reaction, Tubulin was used as the internal reference gene and 2 -ΔΔCT Methods The relative expression of each gene was calculated.
[0101] The primer sequences are:
[0102] TNF-aF:TTGTCTACTCCCAGGTTCTCT;
[0103] TNF-aR:GAGGTTGACTTTCTCCTGGTATG;
[0104] IL-1β-F:GGTGTGGTGACGTTCCCATTA;
[0105] IL-1β-R:ATTGAGGTGGAGAGCTTTCAG;
[0106] IL-6-F:CTTCCATCCAGTTGCCTTCT;
[0107] IL-6-R:CTCCGACTTGTGAAGTGGTATAG;
[0108] α-Tubulin-F:AGCAGCTACTTTGTGGAGTG;
[0109] α-Tubulin-R:TCGGAGATGCGCTTGAATAG.
[0110] Fig.10 The results showed that SA-Lipo of the present invention could significantly reduce the increase in mRNA content of pro-inflammatory factors IL-6, IL-1β and TNF-α caused by LPS stimulation, and reduce the inflammatory level of RAW264.7 cells.
[0111] 3. Effect of SA-Lipo on H2O2-induced oxidative stress
[0112] 1) Effect of SA-Lipo on reactive oxygen species levels in H2O2-induced oxidative stress
[0113] The effect of SA-Lipo on the level of reactive oxygen species was detected using a reactive oxygen species detection kit (Biyuntian, #S0033S). A549 was cultured in a 12-well culture plate for 24 hours, and cells were pretreated with DMEM medium (containing 10% FBS) containing Lipo, SA and SA-Lipo, respectively. The control group and the model group were added with DMEM medium (containing 10% FBS). After 12 hours, the supernatant was discarded, and the cells were treated with DMEM medium (containing 10% FBS) containing 600μM H2O2. The control group was added with DMEM medium (containing 10% FBS). After 4 hours, the supernatant was discarded, and DCFH-DA was diluted with serum-free culture medium at 1:1000, and 500μl was added to each well. The cells were incubated in a cell culture incubator at 37°C for 20 minutes, and finally directly observed and photographed with a fluorescence microscope.
[0114] Fig.11 The results showed that the SA-Lipo of the present invention could significantly reduce the level of reactive oxygen species in oxidative stress induced by H2O2.
[0115] 2) Effect of SA-Lipo on superoxide dismutase activity in H2O2-induced oxidative stress
[0116] The effect of SA-Lipo on superoxide dismutase activity was detected using a total SOD activity detection kit (Biyuntian, #S0101S). A549 was cultured in a T25 cell culture flask for 24 hours, and cells were pretreated with DMEM medium (containing 10% FBS) containing Lipo, SA and SA-Lipo, respectively. The Control group and the Model group were added with DMEM medium (containing 10% FBS). After 12 hours, the supernatant was discarded, and the cells were treated with DMEM medium (containing 10% FBS) containing 600μM H2O2. The Control group was added with DMEM medium (containing 10% FBS). After 4 hours, the supernatant was discarded, and the cells were collected and fully lysed to take the supernatant as the sample to be tested. According to the instructions, the sample to be tested, WST-8 / enzyme working solution, reaction working starting solution, etc. were added to the 96-well plate in sequence, incubated at 37°C for 30 minutes, and the absorbance was measured at 450nm.
[0117] Fig.12 The results showed that SA-Lipo of the present invention could significantly upregulate the activity of superoxide dismutase in oxidative stress induced by H2O2.
[0118] 3) Effect of SA-Lipo on MDA Levels in H2O2-Induced Oxidative Stress
[0119] The effect of SA-Lipo on malondialdehyde level was detected using lipid oxidation (MDA) detection kit. A549 was cultured in T25 cell culture flasks for 24 hours, and cells were pretreated with DMEM medium (containing 10% FBS) containing Lipo, SA and SA-Lipo, respectively. DMEM medium (containing 10% FBS) was added to the Control group and Model group. After 12 hours, the supernatant was discarded, and cells were treated with DMEM medium (containing 10% FBS) containing 600μM H2O2. The Control group was added with DMEM medium (containing 10% FBS). After 4 hours, the supernatant was discarded, and the cells were collected and fully lysed to take the supernatant as the test sample. According to the instructions, MDA detection working solution was added to the test sample, mixed, and heated at 100℃ or boiling water bath for 15 minutes. Cool to room temperature and centrifuge at 1000g for 10 minutes at room temperature. Take 200 microliters of supernatant and add it to a 96-well plate, and then measure the absorbance at 532nm using an enzyme reader.
[0120] Fig.13 The results showed that SA-Lipo of the present invention could significantly reduce the level of malondialdehyde in oxidative stress induced by H2O2.
[0121] 2. Animal experiments and related index determination
[0122] 1. Animal experiment grouping, modeling, and drug administration: 6-8 week old C57BL6 / J male mice were fed adaptively for 7 days, and then injected with saline, Lipo, SA, or SA-Lipo (20 mg / kg, prepared with PBS solution as solvent) intraperitoneally 2 hours before modeling. Then LPS (20 mg / kg) was injected into the tail vein to establish the model. The control group was injected with an equal amount of PBS solution. 24 hours after modeling, the mice were killed and tested.
[0123] 2. Determination of relevant indicators
[0124] 1). Effect of SA-Lipo on pathological damage of lung tissue in mice with LPS-induced septic lung injury
[0125] Fresh lung tissue was fixed in 4% paraformaldehyde solution for 24 hours, then embedded in paraffin and sliced to a thickness of 4 μm. The slides were picked up and dried, and stained with hematoxylin and eosin according to the procedure. The stained slides were dried, sealed, and finally photographed under an optical microscope.
[0126] Fig.14 The results showed that compared with the model group, the alveolar wall of the lung tissue was significantly congested, edematous, and thickened (black arrows), a large number of neutrophil infiltration (green arrows), and the extravascular tissue space was widened and edematous (red arrows). The SA-Lipo treatment group significantly improved the above damage. In addition, SA-Lipo has different degrees of improvement on the damage of other organs.
[0127] 2). Effect of SA-Lipo on lung index in mice with LPS-induced septic lung injury
[0128] When the mice were sacrificed, the whole fresh lung tissue of each mouse was collected and weighed (W1). The weight of the mice was recorded at the time of sacrifice (W2). The lung coefficient was calculated according to the formula: W1 / W2×100%.
[0129] Fig.15 The results showed that the SA-Lipo of the present invention significantly reduced the lung index of mice with septic lung injury caused by LPS and alleviated lung edema.
[0130] 3). Effects of SA-Lipo on the mRNA expression of pro-inflammatory factors IL-6, iNOS and TNF-α in lung tissues of mice with LPS-induced septic lung injury
[0131] According to the instructions of the RNA extraction kit, lung tissue was used to extract total RNA using Trizol reagent, the extracted RNA content was determined by Nanodrop, and the PrimeScript RT kit and gDNA Eraser PerfectReal Time were used to reverse transcribe the mRNA into cDNA. The cDNA of each sample was used as a template to perform qRT-PCR amplification and detection of the target genes (IL-6, IL-1β, TNF-α, and α-Tubulin) to analyze the mRNA expression of each target gene. After the reaction, Tublin was used as the internal reference gene and 2 -ΔΔCT Methods The relative expression of each gene was calculated.
[0132] Primer sequences:
[0133] TNF-aF:TTGTCTACTCCCAGGTTCTCT;
[0134] TNF-aR:GAGGTTGACTTTCTCCTGGTATG;
[0135] iNOS-F:GGAGTGACGGCAAACATGACT;
[0136] iNOS-R: TCGATGCACAACTGGGTGAAC;
[0137] IL-6-F:CTTCCATCCAGTTGCCTTCT;
[0138] IL-6-R:CTCCGACTTGTGAAGTGGTATAG;
[0139] α-Tubulin-F:AGCAGCTACTTTGTGGAGTG;
[0140] α-Tubulin-R:TCGGAGATGCGCTTGAATAG.
[0141] Fig.16 The results showed that the SA-Lipo of the present invention could significantly reduce the mRNA levels of proinflammatory factors IL-6, iNOS and TNF-α in mice with LPS-induced septic lung injury, and the anti-inflammatory effect was better than that of simple SA-Lipo.
[0142] The above are only some embodiments of the present invention. For those skilled in the art, several modifications and improvements can be made without departing from the creative concept of the present invention, which all belong to the protection scope of the present invention.
Claims
1. A 10-shogaol nanoliposome, characterized in that: The invention comprises an original drug 10-shogaol and a liposome encapsulating the original drug 10-shogaol, wherein the mass ratio of the original drug 10-shogaol to the liposome is 1:(3-10); the liposome is prepared from DPPC, cholesterol and DSPE-mPEG2000, and the molar ratio of DPPC, cholesterol and DSPE-mPEG2000 is (75-80):(18-22):
3.
2. The 10-shogaol nanoliposome according to claim 1, characterized in that: The mass ratio of the original drug 10-shogaol to the liposome is 1:(4-6).
3. The 10-shogaol nanoliposome according to claim 2, characterized in that: The drug loading amount of the 10-shogaol nanoliposome is 7-16%.
4. The 10-shogaol nanoliposome according to any one of claims 1 to 3, characterized in that: The encapsulation rate of 10-shogaol by the 10-shogaol nanoliposome is 60-80%.
5. The method for preparing 10-shogaol nanoliposomes according to any one of claims 1 to 4, characterized in that: The steps include: S1. DPPC, cholesterol, DSPE-mPEG2000 and 10-shogaol were dissolved in a solvent, and the solvent was removed by rotary evaporation to obtain a film; S2. Add an aqueous medium to the film obtained in step S1 to hydrate it to obtain a suspension, and then place it on ice for ultrasonication. After the ultrasonication, 10-shogaol nanoliposomes can be obtained.
6. The preparation method according to claim 5, characterized in that: The power of the ultrasound in step S2 is 15-25%.
7. The preparation method according to claim 6, characterized in that: The ultrasonic treatment time in step S2 is 15 to 45 minutes.
8. Use of the 10-shogaol nanoliposome according to any one of claims 1 to 4 in the preparation of a drug for treating septic lung injury.
9. Use of the 10-shogaol nanoliposome according to any one of claims 1 to 4 in the preparation of a drug for treating H2O2-induced oxidative stress.
10. Use of the 10-shogaol nanoliposome according to any one of claims 1 to 4 in the preparation of anti-inflammatory drugs.
Citation Information
Patent Citations
Methylprednisolone immune nanoliposome having active lung targeting property, and preparation method thereof
CN105012238A
Targeted magnetic nanometer nano-liposome and preparation method thereof
CN107441505A
Aerosol inhalation nano-liposome composition for treating pulmonary fibrosis as well as preparation method and application of aerosol inhalation nano-liposome composition
CN118236357A
Liposome, formulation containing liposome, and method of producing formulation
JP2017214395A
